-3.14%
-32.90%
-93.50%
-90.33%
-81.65%
-81.35%
-98.91%
AI Spotlight on APLT
Company Description
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications.Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy.
Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia.Applied Therapeutics, Inc.was incorporated in 2016 and is headquartered in New York, New York.
Market Data
| Last Price | 0.57 |
| Change Percentage | -3.14% |
| Open | 0.59 |
| Previous Close | 0.59 |
| Market Cap ( Millions) | 67 |
| Volume | 1203246 |
| Year High | 10.62 |
| Year Low | 0.55 |
| M A 50 | 2.6 |
| M A 200 | 5.18 |
Financial Ratios
| FCF Yield | -122.43% |
| Dividend Yield | 0.00% |
| ROE | -583.37% |
| Debt / Equity | 33.45% |
| Net Debt / EBIDTA | 105.12% |
| Price To Book | 1.41 |
| Price Earnings Ratio | -0.04 |
| Price To FCF | -0.82 |
| Price To sales | -316.81 |
| EV / EBITDA | 0.33 |
News
- 18:30 - Applied Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Applied Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025 - APLT
- 17:00 - APLT SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Applied Therapeutics, Inc. (APLT)
- 16:00 - Applied Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
- 12:38 - APLT FRAUD ALERT: Applied Therapeutics Sued for Securities Fraud after Stock Drops 80% – Investors Urged to Contact BFA Law by February 18 Deadline (NASDAQ:APLT)
- 12:00 - APLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- 10:45 - Shareholders that lost money on Applied Therapeutics, Inc.(APLT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- 00:19 - ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLT
- Jan -30 - APLT INVESTOR ALERT: Kirby McInerney LLP Notifies Applied Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit
- Jan -30 - Applied Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – APLT
- Jan -30 - Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics Lawsuit - APLT
- Jan -30 - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Applied Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - APLT
- Jan -30 - Applied Therapeutics, Inc. (APLT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Jan -30 - The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Applied Therapeutics, Inc.
- Jan -30 - APLT COURT NEWS: Applied Therapeutics has been Sued for Fraud - Contact BFA Law before February 18 Class Action Deadline if You Suffered Losses
- Jan -30 - APLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Applied Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- Jan -30 - The Gross Law Firm Reminds Applied Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 18, 2025 - APLT
- Jan -30 - Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights - APLT
- Jan -29 - MGPI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MGP Ingredients, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- Jan -29 - APLT Deadline Approaching on February 18, 2025: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Class Action Lawsuit Deadline
- Jan -29 - Shareholders that lost money on Applied Therapeutics, Inc. (APLT) should contact The Gross Law Firm about pending Class Action - APLT
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Biopharmaceutical
Expected Growth : 10.55 %
What the company do ?
Applied Therapeutics, Inc.'s biopharmaceuticals are innovative, small-molecule therapies targeting rare and orphan diseases, focusing on unmet medical needs.
Why we expect these perspectives ?
Applied Therapeutics, Inc.'s biopharmaceutical segment growth of 10.55% is driven by increasing demand for novel therapeutics, strategic partnerships, and a strong pipeline of innovative products. Additionally, the company's focus on rare genetic disorders and unmet medical needs has led to increased investment in R&D, further fueling growth.
Applied Therapeutics, Inc. Products
| Product Range | What is it ? |
|---|---|
| ALD-102 | ALD-102 is a novel, orally administered, small molecule being developed for the treatment of Galactosemia, a rare genetic disorder. |
| AT-007 | AT-007 is a novel, orally administered, small molecule being developed for the treatment of Diabetic Nephropathy, a complication of diabetes. |
| AT-001 | AT-001 is a novel, orally administered, small molecule being developed for the treatment of Citrin Deficiency, a rare genetic disorder. |
Applied Therapeutics, Inc.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Applied Therapeutics, Inc. is medium due to the presence of alternative treatments and therapies available in the market.
Bargaining Power Of Customers
The bargaining power of customers for Applied Therapeutics, Inc. is low due to the specialized nature of their products and services.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Applied Therapeutics, Inc. is medium due to the presence of multiple suppliers in the market.
Threat Of New Entrants
The threat of new entrants for Applied Therapeutics, Inc. is high due to the growing demand for gene therapies and the presence of new entrants in the market.
Intensity Of Rivalry
The intensity of rivalry for Applied Therapeutics, Inc. is high due to the presence of established competitors in the market and the high stakes involved in the gene therapy industry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | -7.44% |
| Debt Cost | 3.95% |
| Equity Weight | 107.44% |
| Equity Cost | 13.51% |
| WACC | 14.22% |
| Leverage | -6.93% |
Applied Therapeutics, Inc. : Quality Control
Applied Therapeutics, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| LGND | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which … |
| PBYI | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 … |
| ARDX | Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, … |
| AMLX | Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax … |
| ITOS | Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ligand Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
Applied Therapeutics
A-Score
1-Year Total Return ->
🥉
Puma Biotechnology
A-Score
1-Year Total Return ->
4
Amylyx Pharmaceuticals
A-Score
1-Year Total Return ->
5
iTeos Therapeutics
A-Score
1-Year Total Return ->
6
